ArticleAnnals of cardiothoracic surgery2012
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
Article in Annals of cardiothoracic surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03762018 (A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Who cites it
24 citing papers in PubMed.
- Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature.Frontiers in oncology · 2023Article
- Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.BMJ open · 2022Article
- Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.Frontiers in oncology · 2022Review
- Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).Journal of experimental & clinical cancer research : CR · 2021Article
- Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Frontiers in oncology · 2021Article
- Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.Frontiers in oncology · 2020Review
- In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.Cancers · 2019Article
- Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.International journal of nanomedicine · 2019Article
- Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.Non-coding RNA research · 2018Review
- Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy.Clinical case reports · 2018Article
- New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.Frontiers in oncology · 2018Review
- Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice.Journal of thoracic disease · 2018Article
- BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.PloS one · 2018Article
- Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.Genes & cancer · 2016Review
- Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.Cell death and differentiation · 2016Article
- Article
- Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).BMC cancer · 2015Article
- The role of interleukin-6 in malignant mesothelioma.Translational lung cancer research · 2015Review
- Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.Oncotarget · 2015Article
- Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.